Working… Menu

Bendamustine, Obinutuzumab, and Venetoclax in Patients With Untreated Mantle Cell Lymphoma

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. Identifier: NCT03872180
Recruitment Status : Recruiting
First Posted : March 13, 2019
Last Update Posted : April 24, 2019
Genentech, Inc.
Information provided by (Responsible Party):
Jonathon Cohen, Emory University

No Study Results Posted on for this Study
Recruitment Status : Recruiting
Estimated Primary Completion Date : April 30, 2021
Estimated Study Completion Date : April 30, 2026